KKRC
JSPR icon

Kohlberg Kravis Roberts & Co’s Jasper Therapeutics JSPR Stock Holding History

Kohlberg Kravis Roberts & Co’s Portfolio JSPR Stock Details JSPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-37,265
Closed -$3.7M – 192
2021
Q2 		$3.7M Buy
37,265
+32,734
+722% +$3.25M 0.02% 60
2021
Q1 		$449K Buy
+4,531
New +$461K ﹤0.01% 80

Other funds holding JSPR

A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
LPARFS
Leverage Partners Absolute Return Fund SPC Cayman Islands Ky1-11111, Cayman Islands $54M AUM
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Kohlberg Kravis Roberts & Co's JSPR Position: Q3 2021 in Review

Kohlberg Kravis Roberts & Co sold out of Jasper Therapeutics (JSPR) in Q3 2021, closing a stake of 37,265 shares — an estimated $3.7M sold.

Kohlberg Kravis Roberts & Co first reported a position in JSPR in Q1 2021 and held it in 2 quarters. The position peaked at $3.7M in Q2 2021. 10 funds tracked by Wall St. Rank hold JSPR as of Q3 2021.

  • Kohlberg Kravis Roberts & Co reported no remaining Jasper Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Kohlberg Kravis Roberts & Co sold 37,265 Jasper Therapeutics shares in Q3 2021, an estimated $3.7M.
  • Kohlberg Kravis Roberts & Co first reported a position in Jasper Therapeutics in Q1 2021 and held it in 2 quarters.
  • Kohlberg Kravis Roberts & Co's Jasper Therapeutics position peaked at $3.7M in Q2 2021.
  • 10 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q3 2021.

Based on Kohlberg Kravis Roberts & Co's 13F filing for Q3 2021, filed 15 Nov 2021.